Alectinib and Brain Metastases: — How It Protects the Brain

It can do both. Alectinib crosses the blood-brain barrier and can act on deposits already in the brain, not only delay the arrival of new ones. In the ALEX trial, patients who already had brain metastases at baseline showed CNS responses — meaning existing lesions shrank — on alectinib. This is one of the properties that distinguishes it from earlier ALK inhibitors such as crizotinib.

Not always. This depends on how many brain metastases you have, how large they are, and whether you have symptoms from them. Because alectinib has strong brain activity, many oncologists choose to treat with alectinib first and reserve radiation for later or for lesions that do not respond. Whole-brain radiation carries its own side effects, including effects on memory, so the decision weighs those risks against the benefit. Ask your oncologist to explain the reasoning for your specific situation.

With brain imaging, usually MRI, which gives more detail than CT for detecting small lesions. Your team will compare each scan with baseline images taken before treatment started. The timing varies between centres — ask how often your brain will be reimaged and whether the schedule is the same as the rest of your staging scans. A response in the brain and a response elsewhere in the body are tracked separately, because they do not always move at the same pace.

The evidence suggests it substantially reduces the risk. In the ALEX trial, the rate of CNS progression over time was considerably lower with alectinib than with crizotinib, including in patients who had no brain metastases at the start. This does not mean brain metastases are impossible on alectinib — but its brain penetration appears to reduce how often they develop compared with treatments that cannot cross the blood-brain barrier.

For some patients, yes. When brain metastases shrink in response to alectinib, symptoms caused by them — such as headaches, weakness, or balance problems — can improve. How much depends on what is causing the symptom: if it is swelling around the lesion, improvement can be noticeable; if it is direct damage to brain tissue, recovery is slower and sometimes incomplete. Tell your team about any neurological symptoms so they can assess whether they are likely to respond to treatment.

If brain metastases progress on alectinib while disease elsewhere is still controlled, your oncologist may consider local treatment — stereotactic radiosurgery to specific lesions, or sometimes whole-brain radiation — rather than switching your systemic treatment immediately. If there is progression both inside and outside the brain, the discussion moves to next-line systemic options, which may include later-generation ALK inhibitors. The plan depends on where progression has occurred and how much.